Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism: A Danish nationwide registry-based study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism : A Danish nationwide registry-based study. / Sindet-Pedersen, Caroline; Pallisgaard, Jannik Langtved; Staerk, Laila; Gerds, Thomas Alexander; Fosbøl, Emil Loldrup; Torp-Pedersen, Christian; Gislason, Gunnar; Olesen, Jonas Bjerring.
In: Thrombosis and Haemostasis, Vol. 117, No. 6, 06.2017, p. 1182-1191.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism
T2 - A Danish nationwide registry-based study
AU - Sindet-Pedersen, Caroline
AU - Pallisgaard, Jannik Langtved
AU - Staerk, Laila
AU - Gerds, Thomas Alexander
AU - Fosbøl, Emil Loldrup
AU - Torp-Pedersen, Christian
AU - Gislason, Gunnar
AU - Olesen, Jonas Bjerring
PY - 2017/6
Y1 - 2017/6
N2 - The approval of rivaroxaban has changed the landscape of treatment of venous thromboembolism (VTE). Little is known about the effect of rivaroxaban compared with vitamin K antagonists (VKA), when used in the everyday clinical practice. The aim of this study was to investigate the safety and effectiveness of rivaroxaban compared with VKAs among patients with VTE, using the Danish nationwide registries. All patients diagnosed with VTE and treated with either rivaroxaban or VKAs between 2013 and 2015 were included. A total of 12,318 patients were diagnosed with VTE and treated with VKAs [n=6,907] or rivaroxaban [n=5,411.]. Combined Cox regression analyses showed that the standardised absolute six-month risk of recurrent VTE was 3.03 % [95 % CI: 2.57 % to 3.48 %] in the rivaroxaban group and 3.13 % [95 % CI: 2.70 % to 3.56 %] in the VKA group (absolute risk difference of -0.11 % [95 % CI: -0.76 % to 0.54 %]). The standardised absolute six-months risk of bleeding was 2.28 % [95 % CI: 1.87 % to 2.67 %] for patients in the rivaroxaban group and 2.10 % [95 % CI: 1.78 % to 2.43 %] in the VKA group (absolute risk difference of 0.18 % [95 % CI: -0.34 % to 0.67]). In conclusion, rivaroxaban was associated with similar risk of recurrent VTE and bleeding compared with VKA.
AB - The approval of rivaroxaban has changed the landscape of treatment of venous thromboembolism (VTE). Little is known about the effect of rivaroxaban compared with vitamin K antagonists (VKA), when used in the everyday clinical practice. The aim of this study was to investigate the safety and effectiveness of rivaroxaban compared with VKAs among patients with VTE, using the Danish nationwide registries. All patients diagnosed with VTE and treated with either rivaroxaban or VKAs between 2013 and 2015 were included. A total of 12,318 patients were diagnosed with VTE and treated with VKAs [n=6,907] or rivaroxaban [n=5,411.]. Combined Cox regression analyses showed that the standardised absolute six-month risk of recurrent VTE was 3.03 % [95 % CI: 2.57 % to 3.48 %] in the rivaroxaban group and 3.13 % [95 % CI: 2.70 % to 3.56 %] in the VKA group (absolute risk difference of -0.11 % [95 % CI: -0.76 % to 0.54 %]). The standardised absolute six-months risk of bleeding was 2.28 % [95 % CI: 1.87 % to 2.67 %] for patients in the rivaroxaban group and 2.10 % [95 % CI: 1.78 % to 2.43 %] in the VKA group (absolute risk difference of 0.18 % [95 % CI: -0.34 % to 0.67]). In conclusion, rivaroxaban was associated with similar risk of recurrent VTE and bleeding compared with VKA.
KW - Anticoagulation
KW - Non-vitamin k antagonist oral anticoagulants
KW - Rivaroxaban
KW - Venous thromboembolism
KW - Vitamin k antagonists
UR - http://www.scopus.com/inward/record.url?scp=85020298086&partnerID=8YFLogxK
U2 - 10.1160/TH16-10-0745
DO - 10.1160/TH16-10-0745
M3 - Journal article
AN - SCOPUS:85020298086
VL - 117
SP - 1182
EP - 1191
JO - Thrombosis et diathesis haemorrhagica
JF - Thrombosis et diathesis haemorrhagica
SN - 0340-6245
IS - 6
ER -
ID: 189396198